• Citer

Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

par Hanker, Ariella B;Garrett, Joan T;Estrada, Mónica Valeria;Moore, Preston D;Ericsson, Paula Gonzalez;Koch, James P;Langley, Emma;Singh, Sharat;Kim, Phillip S;Frampton, Garrett M;Sanford, Eric;Owens, Philip;Becker, Jennifer;Groseclose, Reid MR;Castellino, Stephen;Joensuu, Heikki;Huober, Jens;Brase, Jan Christoph;Majjaj, Samira ;Brohée, Sylvain ;Venet, David ;Brown, David;Baselga, José;Piccart-Gebhart, Martine ;Sotiriou, Christos ;Arteaga, Carlos L
Référence Clinical cancer research, 25, 4, page (1434)
Publication Publié, 2019-02-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Statistiques

Titre:	Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Auteur:	Hanker, Ariella B; Garrett, Joan T; Estrada, Mónica Valeria; Moore, Preston D; Ericsson, Paula Gonzalez; Koch, James P; Langley, Emma; Singh, Sharat; Kim, Phillip S; Frampton, Garrett M; Sanford, Eric; Owens, Philip; Becker, Jennifer; Groseclose, Reid MR; Castellino, Stephen; Joensuu, Heikki; Huober, Jens; Brase, Jan Christoph; Majjaj, Samira; Brohée, Sylvain; Venet, David; Brown, David; Baselga, José; Piccart-Gebhart, Martine; Sotiriou, Christos; Arteaga, Carlos L
Informations sur la publication:	Clinical cancer research, 25, 4, page (1434)
Statut de publication:	Publié, 2019-02-01
Sujet CREF:	Cancérologie
	Sciences bio-médicales et agricoles
	Médecine pathologie humaine
Langue:	Anglais
Identificateurs:	urn:issn:1078-0432
	info:doi/10.1158/1078-0432.CCR-18-4267
	info:pii/25/4/1434
	info:pmid/30770493